$0.78
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Genenta Science SpA is an early-stage company, which engages in the development of first-in-class cell and gene cancer therapies. The company is headquartered in Milan, Milano and currently employs 9 full-time employees. The company went IPO on 2021-12-15. The firm focuses on the development of lentivirus-based gene and cell therapies in cancer. The company uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The firm not only operates locally but also is present in global markets, including the United States.
Country

IT

CEO

Mr. Pierluigi Paracchi

IPO date

2021

Employees

9

ISIN

US36870W1009

Key stats

Open

$0.69

Volume

62.97K

Market cap

$38.35M

Prev. close

$0.78

Impl / hst vl

-

Open interest

$0.00

$0.69

Day’s Range

$0.78

$0.55

52W Range

$2.58

Valuation

33
Valuation score
Overvalued
P/E
-
P/S
-
P/B
1.40
Current ratio
14.16
Debt / Equity
0.35
ROE
-38.46%
Gross margin
-
Income growth
-29.36%
FCF growth
-75.50

Analysts estimates

Consensus rating
Buy

The average rating from top 4 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$7.14
The top 3 analysts forecasts that 12-month price may increase by 815.38%, with a low of $7.07 and a high of $7.35
$7.07
Low
$7.14
Avg
$7.35
High
Current price

Earnings

Q4 ‘25 revenue
$0.00
Q4 ‘25 net income
-$3.03M
Revenue
Net income
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply